<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; light</title>
	<atom:link href="http://www.tapanray.in/tag/light/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>India’s Drug Quality Concerns: Is Light At The End of The Tunnel In Sight Now?</title>
		<link>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now</link>
		<comments>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/#comments</comments>
		<pubDate>Mon, 07 Aug 2023 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[action]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end]]></category>
		<category><![CDATA[events]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[light]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[QR]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tunnel]]></category>
		<category><![CDATA[two=pronged]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10805</guid>
		<description><![CDATA[A brief chronology of some recent events on issues pertaining to patient-health-safety with drugs, as captured below, would possibly generate a mixed feeling for many. This includes a serious concern about, especially generic drug quality safety standards in India, on the one &#8230; <a href="http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indias-drug-quality-concerns-is-light-at-the-end-of-the-tunnel-in-sight-now/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
